PatientsVille.com Logo


Delalutin Medical Research Studies

Up-to-date List of Delalutin Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Delalutin Medical Research Studies

Rank Status Study
1 Recruiting Confirmatory Study of 17P Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery
Condition: Preterm Birth
Interventions: Drug: Hydroxyprogesterone Caproate Injection, 250mg/mL;   Drug: Vehicle
Outcome Measures: Determine if treatment with 17P reduces the rate of preterm birth < 35 weeks, 0 days of gestation in women with a previous singleton spontaneous preterm delivery.;   Determine if 17P reduces the rate of neonatal mortality or morbidity;   Exclude a doubling of the risk of fetal/early infant death;   Preterm birth prior to 32 weeks 0 days of gestation;   Preterm birth prior to 37 weeks 0 days of gestation;   Neonatal death (from minutes after birth until 28 days of life) occurring in liveborns born at 24 weeks gestation or greater
2 Recruiting Prevention of Preterm Labor in Patients With a Previous Episode of Threatened Preterm Labor With Progesterone
Conditions: Preterm Birth;   Obstetric Labor, Premature
Interventions: Drug: 17 α hydroxyprogesterone caproate;   Drug: Placebo
Outcome Measures: To determine if the use of 17 α hydroxyprogesterone caproate can reduce the incidence of preterm birth before 37 weeks of gestation in patients with a previous episode of threatened preterm labor.;   To determine if the use of 17 α hydroxyprogesterone caproate can reduce the incidence of preterm birth before 35 weeks of gestation in patients with a previous episode of threatened preterm labor.;   To determine if the use of 17 α hydroxyprogesterone caproate can reduce the incidence of preterm birth before 32 weeks of gestation in patients with a previous episode of threatened preterm labor.
3 Recruiting Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.
Condition: Pregnancy Complications
Interventions: Drug: 17-Hydroxyprogesterone Caproate;   Other: Caster Oil injections
Outcome Measures: Delivery at 34 weeks gestation;   Neonatal respiratory distress syndrome;   Neonatal grade III - IV IVH;   Neonatal Necrotizing Enterocolitis;   Neonatal length of NICU and total hospital stay;   Length of latency
4 Unknown  Progestagens for the Tertiary Prophylaxis of Preterm Delivery
Conditions: Premature Birth;   Neonatal Complications
Interventions: Drug: 17 alpha-hydroxy progesterone caproate;   Drug: micronized Progesterone;   Other: Control
Outcome Measures: Preterm delivery (37 weeks of gestation);   Delivery <32, <35 wks;   Hospital admissions before delivery;   Gestational age at delivery;   Birth-weight centile;   NICU admission;   days of NICU admission;   days of oxygen supply;   composite neonatal complications;   congenital neonatal anomalies;   congenital neonatal malformations
5 Recruiting A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth
Condition: Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial
Intervention: Drug: ASQ-3, Bayley III, Neurologic exam
Outcome Measure: Determine whether there is a difference in developmental status between children whose mothers received 17P and those who received vehicle in the 17P Efficacy Trial
6 Recruiting Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome
Condition: Polycystic Ovary Syndrome
Interventions: Radiation: 3-D Ultrasound;   Drug: recombinant human chorionic gonadotropin;   Drug: Recombinant follicle stimulating hormone;   Drug: Dexamethasone;   Drug: Adrenocorticotropin;   Drug: Glucose
Outcome Measures: 17-hydroxyprogesterone responses to hCG with and without FSH in PCOS women and normal controls;   Follicle count on 3-D Ultrasound in PCOS women and normal controls;   Adrenal androgen response to ACTH in PCOS women and normal controls;   17-hydroxyprogesterone response to hCG in the setting of reduced insulin secretion in PCOS women
7 Not yet recruiting Progesterone for First Trimester Vaginal Bleeding
Conditions: Threatened Abortion;   Pre-Eclampsia;   Abruptio Placentae;   Fetal Growth Retardation;   Premature Birth
Interventions: Drug: dihydroxyprogesterone caproate;   Drug: Placebo
Outcome Measures: adverse pregnancy outcomes;   Uterine artery blood flow velocimetry;   Placental pathological examination
8 Recruiting Progesterone and Vitamin D3 in Women With LOBC and LABC - A Feasibility Study
Conditions: Breast Cancer;   Locally Advanced Malignant Neoplasm
Interventions: Drug: Cholecalciferol;   Drug: Inj. Progesterone;   Drug: Doxyrubicin or Epirubicin
Outcome Measures: Disease-free survival;   Improvements in overall survival, Tumor response
9 Recruiting The Adrenal Contribution to Androgen Production in Girls During Puberty
Condition: Development
Interventions: Drug: Adrenocorticotropin (ACTH);   Drug: Dexamethasone
Outcome Measures: 17-hydroxyprogesterone levels;   testosterone and androstenedione responses to ACTH
10 Recruiting Meal Timing on Glucose and Hyperandrogenism in PCOS Women
Condition: Polycystic Ovary Syndrome (PCOS) Women
Interventions: Behavioral: Placebo Comparator: Lifestyle counseling Dinner Diet ARM 2;   Other: Active Comparator: Lifestyle counseling ARM 1
Outcome Measures: Changes in Androgens and 17 alpha hydroxyprogesterone serum levels;   Glucose and Insulin Response to OGTT
11 Unknown  Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
Conditions: Hyperandrogenemia;   Obesity;   Polycystic Ovary Syndrome
Interventions: Drug: Leuprolide;   Drug: Dexamethasone;   Drug: recombinant human chorionic gonadotropin
Outcome Measures: 17 hydroxyprogesterone responses to rhCG before and 4 weeks after depot leuprolide administration;   Ovarian hormone precursor responses to rhCG before and 4 weeks after depot leuprolide administration
12 Recruiting Effect of Low-frequency Electroacupuncture (EA) on Polycystic Ovary Syndrome
Condition: Polycystic Ovary Syndrome
Interventions: Other: acupuncture protocol 1;   Other: Acupuncture protocol 2
Outcome Measures: HCG stimulation test;   Laboratory examination;   trans-abdomen ultrasound of the uterus and ovaries;   Physical examination;   Number of Participants with Adverse Events;   menstrual frequency
13 Unknown  Back Pain and Male Sexual Disfunction
Condition: Marriage, Life Event
Outcome Measure:
14 Unknown  Female Sexual Function and Back Pain
Condition: Female Sexual Function
Outcome Measure: Female sexual function
15 Recruiting Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia
Condition: Adrenal Hyperplasia, Congenital
Interventions: Drug: Hydrocortisone;   Drug: Cortisone acetate
Outcome Measures: Androgen levels;   Steroid metabolism;   bone metabolism;   fasting glucose;   body mass index;   Dual-energy X-ray absorptiometry (DXA);   Subjective health status;   waist circumference;   hip circumference;   blood pressure;   fasting insulin;   glycated haemoglobin (Hb1AC);   lipid levels;   c-reactive protein
16 Recruiting Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)
Condition: PCOS
Interventions: Drug: Dexamethasone;   Drug: recombinant human chorionic gonadotropin (r-hCG)
Outcome Measures: 17OHP;   Testosterone;   Androstenedione;   DHEA
17 Not yet recruiting Prevention of Preterm Birth With a Pessary in Singleton Gestations
Conditions: Preterm Birth;   Short Cervix
Intervention: Device: Bioteque cup pessary
Outcome Measures: Preterm birth;   Gestational age at delivery;   Birth weight;   Spontaneous preterm birth;   Spontaneous rupture of membranes;   Neonatal death;   Composite adverse neonatal outcome;   Chorioamnionitis;   Significant adverse maternal effects;   Intolerance to pessary

These studies may lead to new treatments and are adding insight into Delalutin etiology and treatment.

A major focus of Delalutin research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Delalutin